Judy H Huang, MD
Pulmonary Disease · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Huang’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G77534 · Current
Licensed to practise in California · since 1993 · expires 2027-05-31 · University of Chicago, Pritzker School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$167,418
Medicare paid this office $167,418 for 602 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 271 | $54,840 | $114 |
| Long return visit (40+ min) | 149 | $39,943 | $169 |
| Critical care, first 30-74 minutes | 40 | $12,966 | $178 |
| Test to examine how well the lungs exchange gases | 186 | $11,122 | $57 |
| Test to determine lung volumes using sensors | 149 | $8,688 | $56 |
See all 17 services
| Return visit (30+ min) | 271 | $54,840 | $114 |
| Long return visit (40+ min) | 149 | $39,943 | $169 |
| Critical care, first 30-74 minutes | 40 | $12,966 | $178 |
| Test to examine how well the lungs exchange gases | 186 | $11,122 | $57 |
| Test to determine lung volumes using sensors | 149 | $8,688 | $56 |
| New patient visit (60+ min) | 35 | $6,850 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $6,683 | $106 |
| New patient visit (45+ min) | 41 | $5,986 | $146 |
| Short return visit (20+ min) | 54 | $4,833 | $81 |
| Test to measure expiratory airflow and volume | 135 | $3,850 | $27 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 71 | $2,725 | $38 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 72 | $1,529 | $15 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,517 | $117 |
| Influenza vaccine, inactivated | 11 | $900 | $82 |
| Administration of influenza virus vaccine | 13 | $507 | $39 |
| Administration of pneumococcal vaccine | 11 | $399 | $36 |
| Inhalation treatment for airway obstruction or sputum production | 15 | $262 | $9 |
Who their Medicare patients are
602 Original Medicare patients in 2024. Average age 77 · Under 65 4% · 85 and older 21% · Women 66% · Also on Medicaid 8% · Health risk score 1.46. At or below the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 67% · COPD 39% · Coronary heart disease 36% · Atrial fibrillation 26% · Chronic kidney disease 24% · Diabetes 21% · Cancer 21% · Heart failure 19% · Depression 18% · Dementia 8% · Stroke 8%.
The office billed $635,560, Medicare allowed $220,582 and paid $167,418; for 1,783 services of 35 kinds; $2,608 of it was for drugs given in the office and $164,810 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 602 | 1,783 | 77 | 1.46 | $635,560 | $167,418 |
| 2023 | 616 | 1,905 | 78 | 1.32 | $659,040 | $179,928 |
| 2022 | 633 | 2,063 | 78 | 1.38 | $741,551 | $198,603 |
| 2021 | 540 | 1,653 | 77 | 1.33 | $542,076 | $162,964 |
| 2020 | 463 | 1,345 | 77 | 1.46 | $408,613 | $118,951 |
| 2019 | 576 | 1,735 | 77 | 1.51 | $535,552 | $150,570 |
| 2018 | 584 | 1,737 | 76 | 1.40 | $522,113 | $146,692 |
| 2017 | 570 | 1,733 | 75 | 1.48 | $511,007 | $141,323 |
| 2016 | 645 | 2,060 | 76 | 1.51 | $549,766 | $155,784 |
| 2015 | 565 | 1,800 | 76 | 1.46 | $486,515 | $149,266 |
| 2014 | 511 | 1,496 | 76 | 1.38 | $403,282 | $121,040 |
| 2013 | 401 | 1,206 | 76 | 1.38 | $339,851 | $101,227 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 18 services
| Return visit (30+ min) | 252 | $50,859 | $120 |
| Long return visit (40+ min) | 147 | $34,277 | $164 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $14,873 | $108 |
| Test to examine how well the lungs exchange gases | 205 | $13,217 | $58 |
| Critical care, first 30-74 minutes | 34 | $12,396 | $188 |
| New patient visit (45+ min) | 74 | $10,817 | $146 |
| Test to determine lung volumes using sensors | 166 | $9,512 | $56 |
| New patient visit (60+ min) | 34 | $6,713 | $197 |
| Test to measure expiratory airflow and volume | 137 | $4,337 | $28 |
| Short return visit (20+ min) | 39 | $3,632 | $84 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 95 | $3,632 | $37 |
| Pneumococcal vaccine, 23-valent | 25 | $3,270 | $131 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,109 | $120 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 20 | $1,516 | $76 |
| Administration of pneumococcal vaccine | 28 | $983 | $35 |
| Administration of influenza virus vaccine | 23 | $868 | $38 |
| Inhalation treatment for airway obstruction or sputum production | 19 | $564 | $9 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 13 | $51 | $4 |
2022: 18 services
| Return visit (30+ min) | 221 | $42,316 | $115 |
| Long return visit (40+ min) | 164 | $37,712 | $165 |
| Critical care, first 30-74 minutes | 44 | $26,418 | $197 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 79 | $20,588 | $94 |
| Test to examine how well the lungs exchange gases | 189 | $12,688 | $61 |
| Test to determine lung volumes using sensors | 173 | $10,150 | $57 |
| New patient visit (45+ min) | 59 | $9,102 | $154 |
| New patient visit (60+ min) | 36 | $7,469 | $207 |
| Short return visit (20+ min) | 63 | $5,116 | $78 |
| Test to measure expiratory airflow and volume | 133 | $4,200 | $28 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 86 | $3,277 | $38 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $3,069 | $123 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 82 | $2,246 | $22 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 31 | $2,178 | $70 |
| Critical care, each additional 30 minutes | 14 | $1,570 | $98 |
| Administration of influenza virus vaccine | 31 | $1,171 | $38 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 13 | $664 | $51 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 12 | $43 | $4 |
2021: 15 services
| Return visit (30+ min) | 227 | $49,739 | $120 |
| Long return visit (40+ min) | 140 | $37,364 | $172 |
| Critical care, first 30-74 minutes | 27 | $12,017 | $204 |
| Test to examine how well the lungs exchange gases | 167 | $10,783 | $62 |
| Test to determine lung volumes using sensors | 143 | $8,281 | $57 |
| New patient visit (45+ min) | 51 | $7,959 | $156 |
| New patient visit (60+ min) | 30 | $6,469 | $216 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $6,103 | $92 |
| Short return visit (20+ min) | 53 | $5,084 | $81 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 86 | $3,902 | $45 |
| Test to measure expiratory airflow and volume | 97 | $3,187 | $31 |
| Influenza vaccine split virus, preservative free | 38 | $2,480 | $65 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 45 | $1,116 | $23 |
| Administration of influenza virus vaccine | 38 | $825 | $22 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 14 | $56 | $4 |
2020: 16 services
| Return visit (30+ min) | 228 | $45,798 | $106 |
| New patient visit (45+ min) | 58 | $9,339 | $161 |
| Critical care, first 30-74 minutes | 26 | $8,767 | $204 |
| Long return visit (40+ min) | 48 | $7,913 | $144 |
| Test to examine how well the lungs exchange gases | 131 | $7,870 | $58 |
| Test to determine lung volumes using sensors | 108 | $6,204 | $56 |
| Short return visit (20+ min) | 74 | $6,032 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $5,391 | $98 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 90 | $5,187 | $56 |
| Telephone medical discussion with physician, 11-20 minutes | 36 | $3,327 | $79 |
| New patient visit (60+ min) | 12 | $2,441 | $203 |
| Test to measure expiratory airflow and volume | 56 | $2,322 | $39 |
| Influenza vaccine split virus, preservative free | 27 | $1,639 | $61 |
| Administration of influenza virus vaccine | 28 | $584 | $21 |
| Telephone medical discussion with physician, 5-10 minutes | 12 | $569 | $47 |
| Inhalation treatment for airway obstruction or sputum production | 17 | $562 | $19 |
2019: 17 services
| Return visit (30+ min) | 270 | $57,625 | $101 |
| Long return visit (40+ min) | 88 | $13,963 | $134 |
| New patient visit (60+ min) | 72 | $13,173 | $183 |
| New patient visit (45+ min) | 61 | $9,267 | $152 |
| Test to examine how well the lungs exchange gases | 149 | $8,962 | $56 |
| Short return visit (20+ min) | 93 | $8,161 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $7,608 | $91 |
| Test to determine lung volumes using sensors | 118 | $6,540 | $55 |
| Critical care, first 30-74 minutes | 19 | $6,413 | $194 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 106 | $6,279 | $58 |
| Test to measure expiratory airflow and volume | 75 | $2,945 | $36 |
| Influenza vaccine split virus, preservative free | 27 | $1,455 | $54 |
| Inhalation treatment for airway obstruction or sputum production | 36 | $1,034 | $18 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $941 | $63 |
| Administration of influenza virus vaccine | 29 | $595 | $21 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 12 | $53 | $4 |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 11 | $1 | None |
2018: 15 services
| Return visit (30+ min) | 256 | $51,933 | $97 |
| Long return visit (40+ min) | 80 | $15,031 | $131 |
| New patient visit (60+ min) | 71 | $13,338 | $188 |
| Critical care, first 30-74 minutes | 26 | $11,770 | $193 |
| Test to examine how well the lungs exchange gases | 160 | $9,653 | $55 |
| New patient visit (45+ min) | 50 | $6,943 | $139 |
| Test to determine lung volumes using sensors | 120 | $6,708 | $56 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 98 | $5,982 | $60 |
| Short return visit (20+ min) | 68 | $4,940 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $4,919 | $93 |
| Test to measure expiratory airflow and volume | 103 | $4,357 | $37 |
| Inhalation treatment for airway obstruction or sputum production | 41 | $1,570 | $19 |
| Influenza vaccine split virus, preservative free | 26 | $1,140 | $44 |
| Administration of influenza virus vaccine | 26 | $668 | $26 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 17 | $79 | $5 |
2017: 15 services
| Return visit (30+ min) | 229 | $47,609 | $94 |
| Critical care, first 30-74 minutes | 35 | $14,775 | $189 |
| Test to examine how well the lungs exchange gases | 178 | $10,561 | $54 |
| New patient visit (45+ min) | 66 | $9,663 | $146 |
| Long return visit (40+ min) | 61 | $9,470 | $126 |
| Test to determine lung volumes using sensors | 154 | $8,312 | $53 |
| New patient visit (60+ min) | 40 | $7,457 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $6,450 | $92 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 92 | $5,743 | $59 |
| Test to measure expiratory airflow and volume | 120 | $4,688 | $36 |
| Short return visit (20+ min) | 54 | $3,935 | $65 |
| Influenza vaccine split virus, preservative free | 31 | $1,367 | $44 |
| Inhalation treatment for airway obstruction or sputum production | 38 | $1,179 | $18 |
| Administration of influenza virus vaccine | 33 | $1,065 | $32 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 14 | $60 | $4 |
2016: 19 services
| Return visit (30+ min) | 277 | $58,962 | $93 |
| New patient visit (45+ min) | 106 | $15,931 | $150 |
| Test to examine how well the lungs exchange gases | 200 | $11,560 | $53 |
| Critical care, first 30-74 minutes | 24 | $8,834 | $192 |
| Long return visit (40+ min) | 60 | $8,586 | $126 |
| Test to determine lung volumes using sensors | 145 | $7,717 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $7,555 | $91 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 102 | $6,355 | $58 |
| Test to measure expiratory airflow and volume | 139 | $5,489 | $36 |
| Short return visit (20+ min) | 64 | $5,089 | $62 |
| New patient visit (60+ min) | 19 | $3,537 | $186 |
| Influenza vaccine split virus, preservative free | 54 | $1,980 | $37 |
| Administration of influenza virus vaccine | 58 | $1,750 | $30 |
| Inhalation treatment for airway obstruction or sputum production | 52 | $1,718 | $18 |
| New patient visit (30+ min) | 15 | $1,511 | $101 |
| Pneumococcal vaccine, 23-valent | 13 | $1,146 | $88 |
| Test to determine lung volumes using gas dilution or washout | 26 | $924 | $36 |
| Administration of pneumococcal vaccine | 19 | $577 | $30 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 17 | $72 | $4 |
2015: 19 services
| Return visit (30+ min) | 243 | $53,197 | $99 |
| New patient visit (45+ min) | 98 | $15,295 | $156 |
| Test to examine how well the lungs exchange gases | 167 | $10,559 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $9,182 | $96 |
| Test to determine lung volumes using sensors | 139 | $8,039 | $57 |
| Long return visit (40+ min) | 50 | $7,919 | $132 |
| Critical care, first 30-74 minutes | 22 | $7,831 | $206 |
| Short return visit (20+ min) | 82 | $6,767 | $69 |
| Test to measure expiratory airflow and volume | 143 | $6,045 | $39 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 66 | $4,239 | $62 |
| Pneumococcal vaccine, 13-valent | 23 | $3,468 | $151 |
| New patient visit (60+ min) | 15 | $2,740 | $183 |
| New patient visit (30+ min) | 20 | $2,017 | $101 |
| Administration of influenza virus vaccine | 39 | $1,220 | $31 |
| Inhalation treatment for airway obstruction or sputum production | 23 | $939 | $19 |
| Influenza vaccine split virus, preservative free | 23 | $819 | $36 |
| Administration of pneumococcal vaccine | 26 | $790 | $30 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 16 | $284 | $18 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 32 | $169 | $5 |
2014: 18 services
| Return visit (30+ min) | 197 | $40,773 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $15,804 | $92 |
| New patient visit (45+ min) | 92 | $13,693 | $149 |
| Long return visit (40+ min) | 57 | $8,797 | $129 |
| Test to examine how well the lungs exchange gases | 125 | $6,886 | $54 |
| Short return visit (20+ min) | 82 | $6,048 | $62 |
| Test to determine lung volumes using sensors | 106 | $5,639 | $53 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 82 | $5,094 | $61 |
| New patient visit (60+ min) | 20 | $3,654 | $183 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,238 | $180 |
| Test to measure expiratory airflow and volume | 79 | $2,961 | $35 |
| Administration of influenza virus vaccine | 38 | $1,154 | $30 |
| Pneumococcal vaccine, 23-valent | 17 | $1,083 | $64 |
| Influenza vaccine split virus, preservative free | 24 | $785 | $33 |
| Administration of pneumococcal vaccine | 17 | $516 | $30 |
| Inhalation treatment for airway obstruction or sputum production | 11 | $266 | $19 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 14 | $248 | $18 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 22 | $116 | $5 |
2013: 15 services
| Return visit (30+ min) | 169 | $34,540 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $11,690 | $90 |
| New patient visit (45+ min) | 59 | $8,599 | $146 |
| Long return visit (40+ min) | 50 | $8,054 | $122 |
| Short return visit (20+ min) | 73 | $6,366 | $64 |
| Test to examine how well the lungs exchange gases | 86 | $5,884 | $63 |
| Test to determine lung volumes using sensors | 78 | $4,823 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,845 | $175 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 54 | $3,223 | $60 |
| Test to measure expiratory airflow and volume | 61 | $2,722 | $38 |
| Extended inpatient or observation hospital service, first hour | 13 | $1,279 | $80 |
| Administration of influenza virus vaccine | 18 | $547 | $30 |
| Inhalation treatment for airway obstruction or sputum production | 12 | $324 | $18 |
| Influenza vaccine, trivalent, split virus, preservative-free, 0.5 ml dosage | 12 | $146 | $12 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 14 | $67 | $4 |
Drugs they prescribed that Part D paid
$887,991
Pharmacies billed $887,991 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,877) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
726 generic and 1,151 brand-name prescriptions · $887,991 in drug cost · 225 antibiotic prescriptions to 86 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 339 | $288,031 | $850 |
| Anoro Ellipta | 123 | $94,446 | $768 |
| Breo Ellipta | 141 | $71,718 | $509 |
| Stiolto Respimat | 57 | $40,471 | $710 |
| Pirfenidone | 23 | $35,114 | $1,527 |
See all 33 drugs
| Trelegy Ellipta | 339 | $288,031 | $850 |
| Anoro Ellipta | 123 | $94,446 | $768 |
| Breo Ellipta | 141 | $71,718 | $509 |
| Stiolto Respimat | 57 | $40,471 | $710 |
| Pirfenidone | 23 | $35,114 | $1,527 |
| Spiriva Handihaler | 40 | $34,550 | $864 |
| Eliquis | 36 | $27,020 | $751 |
| Incruse Ellipta | 39 | $21,783 | $559 |
| Wixela Inhub | 69 | $13,380 | $194 |
| Spiriva Respimat | 17 | $12,938 | $761 |
| Advair Hfa | 28 | $11,261 | $402 |
| Dulera | 25 | $10,148 | $406 |
| Symbicort | 36 | $10,055 | $279 |
| Itraconazole | 13 | $9,076 | $698 |
| Arnuity Ellipta | 28 | $7,784 | $278 |
| Fluticasone-Salmeterol | 51 | $6,317 | $124 |
| Pulmicort Flexhaler | 15 | $5,495 | $366 |
| Breyna | 13 | $3,948 | $304 |
| Fluticasone Propionate Hfa | 11 | $3,893 | $354 |
| Advair Diskus | 21 | $3,783 | $180 |
| Albuterol Sulfate Hfa | 98 | $3,445 | $35 |
| Ventolin Hfa | 45 | $3,239 | $72 |
| Azithromycin | 128 | $2,311 | $18 |
| Ethambutol | 35 | $2,064 | $59 |
| Levalbuterol Tartrate Hfa | 16 | $1,084 | $68 |
| Prednisone | 117 | $934 | $8 |
| Fluticasone Propionate | 13 | $424 | $33 |
| Famotidine | 18 | $340 | $19 |
| Amoxicillin-Clavulanate Potass | 29 | $293 | $10 |
| Montelukast | 32 | $286 | $9 |
| Sulfamethoxazole-Trimethoprim | 38 | $254 | $7 |
| Furosemide | 26 | $97 | $4 |
| Doxycycline Hyclate | 13 | $94 | $7 |
Year by year
| 2024 | 1,877 | 319 | 0% (0) | 61% | $887,991 |
| 2023 | 1,929 | 343 | 0% (0) | 65% | $1,391,100 |
| 2022 | 1,893 | 317 | 0% (0) | 66% | $1,314,521 |
| 2021 | 1,673 | 268 | 0% (0) | 65% | $957,497 |
| 2020 | 1,620 | 285 | 0% (0) | 67% | $1,142,814 |
| 2019 | 1,674 | 273 | 0% (0) | 65% | $903,609 |
| 2018 | 1,726 | 253 | None | 65% | $746,365 |
| 2017 | 1,602 | 248 | None | 70% | $623,461 |
| 2016 | 1,506 | 247 | None | 68% | $497,865 |
| 2015 | 1,401 | 227 | 0% (0) | 67% | $436,530 |
| 2014 | 1,273 | 230 | None | 67% | $303,139 |
| 2013 | 1,357 | 200 | None | 66% | $303,402 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 36 drugs
| Ofev | 32 | $443,416 | $13,857 |
| Trelegy Ellipta | 221 | $200,274 | $906 |
| Anoro Ellipta | 173 | $128,273 | $741 |
| Breo Ellipta | 166 | $100,743 | $607 |
| Pirfenidone | 38 | $97,793 | $2,573 |
| Spiriva Handihaler | 74 | $67,499 | $912 |
| Advair Diskus | 84 | $52,626 | $626 |
| Stiolto Respimat | 50 | $38,641 | $773 |
| Incruse Ellipta | 38 | $33,405 | $879 |
| Symbicort | 62 | $32,185 | $519 |
| Atovaquone | 15 | $22,259 | $1,484 |
| Wixela Inhub | 64 | $20,568 | $321 |
| Spiriva Respimat | 26 | $19,217 | $739 |
| Advair Hfa | 37 | $19,023 | $514 |
| Eliquis | 17 | $12,844 | $756 |
| Fluticasone-Salmeterol | 33 | $8,061 | $244 |
| Itraconazole | 12 | $7,411 | $618 |
| Dulera | 18 | $6,578 | $365 |
| Pulmicort Flexhaler | 15 | $6,103 | $407 |
| Serevent Diskus | 12 | $5,523 | $460 |
| Albuterol Sulfate Hfa | 117 | $4,767 | $41 |
| Arnuity Ellipta | 16 | $4,229 | $264 |
| Ventolin Hfa | 50 | $3,669 | $73 |
| Azithromycin | 103 | $2,082 | $20 |
| Ethambutol | 28 | $1,551 | $55 |
| Levalbuterol Tartrate Hfa | 16 | $1,031 | $64 |
| Prednisone | 101 | $789 | $8 |
| Fluticasone Propionate | 22 | $600 | $27 |
| Montelukast | 26 | $451 | $17 |
| Azelastine | 12 | $426 | $35 |
| Amoxicillin-Clavulanate Potass | 21 | $350 | $17 |
| Sulfamethoxazole-Trimethoprim | 41 | $332 | $8 |
| Famotidine | 23 | $320 | $14 |
| Doxycycline Hyclate | 18 | $313 | $17 |
| Omeprazole | 13 | $125 | $10 |
| Furosemide | 29 | $76 | $3 |
2022: 32 drugs
| Esbriet | 28 | $296,881 | $10,603 |
| Trelegy Ellipta | 242 | $185,203 | $765 |
| Pirfenidone | 13 | $98,550 | $7,581 |
| Anoro Ellipta | 150 | $98,340 | $656 |
| Breo Ellipta | 180 | $96,277 | $535 |
| Spiriva Handihaler | 120 | $94,970 | $791 |
| Advair Diskus | 64 | $38,727 | $605 |
| Stiolto Respimat | 38 | $36,235 | $954 |
| Wixela Inhub | 89 | $34,895 | $392 |
| Symbicort | 62 | $34,187 | $551 |
| Spiriva Respimat | 32 | $24,232 | $757 |
| Incruse Ellipta | 24 | $22,210 | $925 |
| Atovaquone | 16 | $22,146 | $1,384 |
| Advair Hfa | 39 | $21,029 | $539 |
| Fluticasone-Salmeterol | 46 | $9,206 | $200 |
| Albuterol Sulfate Hfa | 134 | $7,257 | $54 |
| Serevent Diskus | 12 | $5,421 | $452 |
| Ventolin Hfa | 73 | $5,149 | $71 |
| Itraconazole | 21 | $3,504 | $167 |
| Azithromycin | 90 | $2,097 | $23 |
| Ethambutol | 33 | $1,863 | $56 |
| Rifampin | 13 | $1,195 | $92 |
| Montelukast | 36 | $788 | $22 |
| Ondansetron | 12 | $706 | $59 |
| Fluticasone Propionate | 20 | $514 | $26 |
| Famotidine | 26 | $319 | $12 |
| Prednisone | 52 | $294 | $6 |
| Doxycycline Hyclate | 14 | $293 | $21 |
| Amoxicillin-Clavulanate Potass | 18 | $208 | $12 |
| Furosemide | 28 | $103 | $4 |
| Isoniazid | 11 | $29 | $3 |
| Omeprazole | 17 | $23 | $1 |
2021: 30 drugs
| Esbriet | 16 | $159,516 | $9,970 |
| Trelegy Ellipta | 125 | $99,401 | $795 |
| Anoro Ellipta | 166 | $94,579 | $570 |
| Spiriva | 104 | $90,749 | $873 |
| Breo Ellipta | 145 | $77,818 | $537 |
| Advair Diskus | 69 | $46,361 | $672 |
| Symbicort | 74 | $38,367 | $518 |
| Stiolto Respimat | 41 | $38,168 | $931 |
| Wixela Inhub | 99 | $32,356 | $327 |
| Incruse Ellipta | 27 | $25,611 | $949 |
| Spiriva Respimat | 40 | $23,986 | $600 |
| Advair Hfa | 36 | $21,176 | $588 |
| Atovaquone | 15 | $15,953 | $1,064 |
| Flovent Hfa | 19 | $14,889 | $784 |
| Itraconazole | 21 | $6,863 | $327 |
| Fluticasone-Salmeterol | 31 | $6,211 | $200 |
| Serevent Diskus | 14 | $6,133 | $438 |
| Albuterol Sulfate Hfa | 112 | $5,663 | $51 |
| Azithromycin | 116 | $3,036 | $26 |
| Ventolin Hfa | 36 | $2,472 | $69 |
| Ethambutol | 34 | $1,891 | $56 |
| Montelukast | 46 | $872 | $19 |
| Rifampin | 18 | $811 | $45 |
| Amoxicillin-Clavulanate Potass | 19 | $406 | $21 |
| Prednisone | 52 | $344 | $7 |
| Famotidine | 17 | $292 | $17 |
| Omeprazole | 15 | $168 | $11 |
| Doxycycline Hyclate | 13 | $162 | $12 |
| Sulfamethoxazole-Trimethoprim | 17 | $125 | $7 |
| Furosemide | 23 | $120 | $5 |
2020: 34 drugs
| Esbriet | 30 | $308,260 | $10,275 |
| Ofev | 14 | $147,224 | $10,516 |
| Spiriva | 92 | $79,072 | $859 |
| Anoro Ellipta | 123 | $77,750 | $632 |
| Advair Diskus | 94 | $64,536 | $687 |
| Trelegy Ellipta | 74 | $58,065 | $785 |
| Breo Ellipta | 108 | $52,056 | $482 |
| Symbicort | 87 | $48,469 | $557 |
| Wixela Inhub | 104 | $37,211 | $358 |
| Incruse Ellipta | 50 | $32,448 | $649 |
| Stiolto Respimat | 32 | $27,323 | $854 |
| Flovent Hfa | 37 | $25,708 | $695 |
| Advair Hfa | 41 | $23,679 | $578 |
| Serevent Diskus | 28 | $14,804 | $529 |
| Spiriva Respimat | 18 | $13,612 | $756 |
| Combivent Respimat | 11 | $9,187 | $835 |
| Itraconazole | 16 | $8,176 | $511 |
| Eliquis | 11 | $5,918 | $538 |
| Fluticasone-Salmeterol | 19 | $5,915 | $311 |
| Atrovent Hfa | 12 | $5,817 | $485 |
| Azithromycin | 97 | $3,694 | $38 |
| Ventolin Hfa | 48 | $3,606 | $75 |
| Proair Hfa | 32 | $2,966 | $93 |
| Albuterol Sulfate Hfa | 61 | $2,833 | $46 |
| Ethambutol | 36 | $1,694 | $47 |
| Montelukast | 52 | $1,110 | $21 |
| Rifampin | 14 | $1,014 | $72 |
| Prednisone | 61 | $464 | $8 |
| Fluticasone Propionate | 15 | $377 | $25 |
| Doxycycline Hyclate | 17 | $309 | $18 |
| Famotidine | 12 | $214 | $18 |
| Amoxicillin-Clavulanate Potass | 17 | $174 | $10 |
| Sulfamethoxazole-Trimethoprim | 20 | $129 | $6 |
| Furosemide | 17 | $77 | $5 |
2019: 29 drugs
| Esbriet | 22 | $221,375 | $10,062 |
| Anoro Ellipta | 134 | $81,138 | $606 |
| Advair Diskus | 134 | $80,520 | $601 |
| Spiriva | 107 | $78,287 | $732 |
| Symbicort | 105 | $56,186 | $535 |
| Trelegy Ellipta | 53 | $41,420 | $782 |
| Breo Ellipta | 81 | $32,855 | $406 |
| Stiolto Respimat | 38 | $27,590 | $726 |
| Wixela Inhub | 71 | $24,803 | $349 |
| Advair Hfa | 34 | $24,332 | $716 |
| Incruse Ellipta | 54 | $23,573 | $437 |
| Flovent Hfa | 24 | $12,763 | $532 |
| Atovaquone | 14 | $12,634 | $902 |
| Fluticasone-Salmeterol | 27 | $9,159 | $339 |
| Itraconazole | 15 | $8,493 | $566 |
| Serevent Diskus | 11 | $8,202 | $746 |
| Proair Hfa | 57 | $4,700 | $82 |
| Ventolin Hfa | 57 | $3,779 | $66 |
| Azithromycin | 129 | $3,207 | $25 |
| Ethambutol | 66 | $2,291 | $35 |
| Rifampin | 23 | $1,339 | $58 |
| Montelukast | 61 | $916 | $15 |
| Prednisone | 90 | $674 | $7 |
| Doxycycline Hyclate | 21 | $448 | $21 |
| Fluticasone Propionate | 11 | $373 | $34 |
| Amoxicillin-Clavulanate Potass | 27 | $331 | $12 |
| Furosemide | 28 | $270 | $10 |
| Levofloxacin | 16 | $241 | $15 |
| Sulfamethoxazole-Trimethoprim | 23 | $204 | $9 |
2018: 27 drugs
| Esbriet | 22 | $215,669 | $9,803 |
| Advair Diskus | 252 | $143,211 | $568 |
| Spiriva | 166 | $101,473 | $611 |
| Anoro Ellipta | 109 | $66,037 | $606 |
| Symbicort | 130 | $52,079 | $401 |
| Advair Hfa | 49 | $26,184 | $534 |
| Breo Ellipta | 53 | $19,532 | $369 |
| Incruse Ellipta | 30 | $15,886 | $530 |
| Stiolto Respimat | 29 | $13,522 | $466 |
| Itraconazole | 14 | $11,242 | $803 |
| Combivent Respimat | 13 | $9,861 | $759 |
| Flovent Hfa | 26 | $9,604 | $369 |
| Ventolin Hfa | 73 | $4,550 | $62 |
| Mycophenolate Mofetil | 29 | $3,655 | $126 |
| Proair Hfa | 46 | $3,352 | $73 |
| Ethambutol | 76 | $2,753 | $36 |
| Azithromycin | 126 | $1,946 | $15 |
| Rifampin | 45 | $1,944 | $43 |
| Proventil Hfa | 11 | $880 | $80 |
| Prednisone | 108 | $720 | $7 |
| Ipratropium | 19 | $627 | $33 |
| Montelukast | 48 | $585 | $12 |
| Levofloxacin | 26 | $467 | $18 |
| Fluticasone Propionate | 23 | $440 | $19 |
| Amoxicillin-Clavulanate Potass | 29 | $375 | $13 |
| Sulfamethoxazole-Trimethoprim | 26 | $164 | $6 |
| Furosemide | 12 | $121 | $10 |
2017: 29 drugs
| Spiriva | 278 | $138,704 | $499 |
| Esbriet | 15 | $134,807 | $8,987 |
| Advair Diskus | 278 | $130,247 | $469 |
| Symbicort | 109 | $39,329 | $361 |
| Advair Hfa | 57 | $31,369 | $550 |
| Anoro Ellipta | 64 | $24,446 | $382 |
| Incruse Ellipta | 24 | $12,390 | $516 |
| Brovana | 12 | $11,371 | $948 |
| Spiriva Respimat | 17 | $10,528 | $619 |
| Itraconazole | 19 | $9,645 | $508 |
| Atovaquone | 11 | $6,511 | $592 |
| Stiolto Respimat | 14 | $5,983 | $427 |
| Flovent Hfa | 19 | $5,860 | $308 |
| Proair Hfa | 73 | $5,429 | $74 |
| Breo Ellipta | 12 | $4,493 | $374 |
| Qvar | 17 | $3,613 | $213 |
| Ventolin Hfa | 42 | $2,483 | $59 |
| Ethambutol | 22 | $944 | $43 |
| Proventil Hfa | 12 | $940 | $78 |
| Ipratropium | 23 | $897 | $39 |
| Azithromycin | 85 | $845 | $10 |
| Prednisone | 117 | $731 | $6 |
| Levalbuterol Tartrate Hfa | 12 | $703 | $59 |
| Montelukast | 34 | $317 | $9 |
| Fluticasone Propionate | 19 | $310 | $16 |
| Amoxicillin-Clavulanate Potass | 22 | $303 | $14 |
| Levofloxacin | 22 | $248 | $11 |
| Albuterol Sulfate | 13 | $156 | $12 |
| Sulfamethoxazole-Trimethoprim | 30 | $110 | $4 |
2016: 27 drugs
| Spiriva | 305 | $132,419 | $434 |
| Advair Diskus | 279 | $125,862 | $451 |
| Esbriet | 12 | $99,316 | $8,276 |
| Advair Hfa | 48 | $24,104 | $502 |
| Symbicort | 75 | $22,725 | $303 |
| Brovana | 12 | $10,457 | $871 |
| Combivent Respimat | 17 | $9,162 | $539 |
| Itraconazole | 22 | $8,008 | $364 |
| Flovent Hfa | 22 | $7,129 | $324 |
| Stiolto Respimat | 15 | $7,056 | $470 |
| Qvar | 13 | $6,176 | $475 |
| Serevent Diskus | 15 | $5,166 | $344 |
| Proair Hfa | 82 | $4,448 | $54 |
| Xopenex Hfa | 25 | $2,786 | $111 |
| Ventolin Hfa | 22 | $1,480 | $67 |
| Azithromycin | 74 | $1,377 | $19 |
| Prednisone | 110 | $752 | $7 |
| Levofloxacin | 37 | $489 | $13 |
| Montelukast | 31 | $482 | $16 |
| Albuterol Sulfate | 16 | $471 | $29 |
| Ethambutol | 15 | $433 | $29 |
| Ipratropium | 17 | $432 | $25 |
| Amoxicillin-Clavulanate Potass | 17 | $413 | $24 |
| Fluticasone Propionate | 20 | $382 | $19 |
| Omeprazole | 18 | $337 | $19 |
| Sulfamethoxazole-Trimethoprim | 38 | $276 | $7 |
| Furosemide | 25 | $198 | $8 |
2015: 24 drugs
| Spiriva | 301 | $132,243 | $439 |
| Esbriet | 13 | $105,548 | $8,119 |
| Advair Diskus | 197 | $79,966 | $406 |
| Advair Hfa | 58 | $23,261 | $401 |
| Symbicort | 73 | $22,908 | $314 |
| Brovana | 16 | $11,156 | $697 |
| Itraconazole | 12 | $7,040 | $587 |
| Flovent Hfa | 25 | $6,986 | $279 |
| Qvar | 15 | $6,187 | $412 |
| Proair Hfa | 97 | $5,898 | $61 |
| Combivent Respimat | 18 | $5,843 | $325 |
| Xopenex Hfa | 35 | $3,038 | $87 |
| Azithromycin | 80 | $1,236 | $15 |
| Ethambutol | 17 | $1,052 | $62 |
| Prednisone | 91 | $780 | $9 |
| Montelukast | 39 | $585 | $15 |
| Albuterol Sulfate | 33 | $322 | $10 |
| Fluticasone Propionate | 25 | $312 | $12 |
| Omeprazole | 16 | $208 | $13 |
| Sulfamethoxazole-Trimethoprim | 32 | $198 | $6 |
| Amoxicillin-Clavulanate Potass | 15 | $191 | $13 |
| Spironolactone | 19 | $182 | $10 |
| Levofloxacin | 17 | $150 | $9 |
| Furosemide | 20 | $76 | $4 |
2014: 20 drugs
| Spiriva | 300 | $124,553 | $415 |
| Advair Diskus | 201 | $80,541 | $401 |
| Advair Hfa | 47 | $19,920 | $424 |
| Symbicort | 60 | $17,314 | $289 |
| Itraconazole | 17 | $8,232 | $484 |
| Flovent Hfa | 25 | $7,916 | $317 |
| Proair Hfa | 80 | $5,859 | $73 |
| Xopenex Hfa | 39 | $2,985 | $77 |
| Ethambutol | 20 | $2,752 | $138 |
| Rifampin | 11 | $2,070 | $188 |
| Azithromycin | 66 | $1,571 | $24 |
| Montelukast | 29 | $1,035 | $36 |
| Prednisone | 100 | $1,008 | $10 |
| Ventolin Hfa | 15 | $716 | $48 |
| Fluticasone Propionate | 29 | $449 | $15 |
| Omeprazole | 21 | $339 | $16 |
| Levofloxacin | 24 | $318 | $13 |
| Amox Tr-Potassium Clavulanate | 14 | $273 | $20 |
| Sulfamethoxazole-Trimethoprim | 23 | $149 | $6 |
| Furosemide | 11 | $33 | $3 |
2013: 22 drugs
| Spiriva | 340 | $132,077 | $388 |
| Advair Diskus | 226 | $92,204 | $408 |
| Advair Hfa | 37 | $13,707 | $370 |
| Itraconazole | 12 | $9,257 | $771 |
| Symbicort | 19 | $6,573 | $346 |
| Flovent Hfa | 24 | $5,905 | $246 |
| Proair Hfa | 78 | $3,867 | $50 |
| Ethambutol | 20 | $2,906 | $145 |
| Xopenex Hfa | 32 | $2,580 | $81 |
| Ventolin Hfa | 33 | $1,936 | $59 |
| Avelox | 11 | $1,778 | $162 |
| Azithromycin | 61 | $1,667 | $27 |
| Montelukast | 26 | $1,473 | $57 |
| Mycophenolate Mofetil | 11 | $1,313 | $119 |
| Clotrimazole | 17 | $876 | $52 |
| Prednisone | 130 | $769 | $6 |
| Fluticasone Propionate | 22 | $492 | $22 |
| Sulfamethoxazole-Trimethoprim | 56 | $303 | $5 |
| Levofloxacin | 27 | $284 | $11 |
| Omeprazole | 16 | $277 | $17 |
| Ciprofloxacin | 11 | $144 | $13 |
| Furosemide | 23 | $67 | $3 |
Money from drug and device companies
$273 in 2025
| 2025 | 5 | 11 | None | $273 |
| 2024 | 4 | 13 | None | $383 |
| 2023 | 2 | 5 | None | $95 |
| 2021 | 1 | 1 | None | $23 |
| 2019 | 1 | 2 | None | $140 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boehringer Ingelheim Pharmaceuticals | Ofev | $141 | 5 payments
|
| GlaxoSmithKline | Nucala | $61 | 2 payments
|
| Insmed | Arikayce | $34 | 2 payments
|
| Genzyme | Dupixent | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $16 | 1 payment
|
See all 11 published payments
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-18 | Jascayd | $28 |
| Insmed | Meals · 2025-10-02 | Arikayce | $15 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-25 | Tezspire | $16 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-04 | Ofev | $27 |
| GlaxoSmithKline | Meals · 2025-08-27 | Nucala | $29 |
| Insmed | Meals · 2025-08-23 | Arikayce | $19 |
| GlaxoSmithKline | Meals · 2025-07-15 | Nucala | $32 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-20 | Ofev | $34 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-06 | Ofev | $27 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-07 | Ofev | $26 |
| Genzyme | Meals · 2025-02-07 | Dupixent | $21 |
See earlier years (2024, 2023, 2021, 2019)
2024: $383
| Boehringer Ingelheim Pharmaceuticals | Ofev | $292 | 9 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $46 | 2 payments
|
| Philips North America | (8874) Incourage | $30 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Airsupra | $16 | 1 payment
|
2023: $95
| Boehringer Ingelheim Pharmaceuticals | Ofev | $78 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Airsupra | $18 | 1 payment
|
2021: $23
| Insmed | Arikayce | $23 | 1 payment
|
2019: $140
| Insmed | Arikayce | $140 | 2 payments
|
Professional record
- NPI
- 1861504003
- Licence
- CA G77534California G77534: Current · expires 2027-05-31
- Trained
- University of Chicago, Pritzker School of Medicine, 1992
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-08-31
- NPI last updated
- 2020-05-13
- NPI record certified
- 2020-05-13
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 301 Industrial Rd, San Carlos, CA, 94070